|
|
Article: FDA approves treatment for use in bed-wetting; DDAVP receives new indication for nocturnal enuresis. (desmopressin acetate nasal spray)
- Article from:
- PR Newswire
- Article date:
- December 5, 1989
CopyrightCOPYRIGHT 1989 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA APPROVES TREATMENT FOR USE IN BED-WETTING;
DDAVP RECEIVES NEW INDICATION FOR NOCTURNAL ENURESIS
FT. WASHINGTON, Pa., Dec. 5 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Rorer Pharmaceutical Corporation (NYSE: ROR), a subsidiary of Rorer Group, Inc., approval to market DDAVP(R) Nasal Spray (desmopressin acetate) for the treatment of primary nocturnal enuresis (bed-wetting).
"For years, physicians have been unable to pinpoint the exact cause of bed-wetting," according to Kenneth Miller, M.D., pediatric nephrologist and enuresis specialist at Lutheran General Children's Medical Center, Park Ridge, Ill. "For ...